Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.
Company Growth (employees)
Type
Public
HQ
New York, US
Size (employees)
116 (est)
Synergy Pharmaceuticals is headquartered in New York, US

Synergy Pharmaceuticals Office Locations

Synergy Pharmaceuticals has an office in New York
New York, US (HQ)
420 Lexington Ave

Synergy Pharmaceuticals Data and Metrics

Synergy Pharmaceuticals Financial Metrics

Synergy Pharmaceuticals's revenue was reported to be $98 k in Q1, 2017
USD

Revenue (Q1, 2017)

98 k

Gross profit (Q1, 2017)

(1.7 m)

Gross profit margin (Q1, 2017), %

(1742%)

Net income (Q1, 2017)

(64.6 m)

EBIT (Q1, 2017)

(62.7 m)

Market capitalization (17-Aug-2017)

652.4 m

Cash (31-Mar-2017)

139.3 m
Synergy Pharmaceuticals's current market capitalization is $652.4 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

EBIT

(176.8 m)(94.3 m)(99.8 m)(42.4 m)

Net Income

(171.2 m)(95.7 m)(117.5 m)(198.6 m)
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

98 k

Cost of goods sold

1.8 m

Gross profit

(1.7 m)

Gross profit Margin, %

(1742%)

R&D expense

20.9 m18.2 m19.5 m20.4 m21.2 m26.6 m24.6 m19.1 m

General and administrative expense

2.5 m4.6 m7.4 m2.7 m6.4 m10.2 m13.9 m41.9 m

Operating expense total

23.5 m22.8 m26.9 m23.2 m27.6 m36.9 m38.5 m61 m

EBIT

(23.5 m)(22.8 m)(26.9 m)(23.2 m)(27.6 m)(36.9 m)(38.5 m)(62.7 m)

EBIT margin, %

(64007%)

Net Income

(23 m)(27.4 m)(33.7 m)(26 m)(59.9 m)(38.6 m)(40.2 m)(64.6 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

18.1 m146.5 m61.7 m82.4 m

Accounts Receivable

554 k

Inventories

3.7 m3.8 m3.3 m5.6 m

Current Assets

71.9 m200.2 m115.1 m88.9 m

PP&E

589 k642 k531 k593 k

Total Assets

72.6 m213.3 m115.9 m89.9 m

Accounts Payable

13.5 m13.9 m13.3 m15.6 m

Current Liabilities

15.7 m18.3 m19.6 m29.4 m

Total Liabilities

52.3 m

Additional Paid-in Capital

226.5 m261.7 m329.2 m620.5 m

Retained Earnings

(171.2 m)(266.9 m)(384.4 m)(583 m)

Total Equity

55.3 m(5.2 m)(55.2 m)37.5 m

Financial Leverage

1.3 x-41.4 x-2.1 x2.4 x
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

12.8 m78.7 m61.7 m41.9 m84.2 m141.2 m109.1 m139.3 m

Accounts Receivable

6.3 m

Inventories

9.6 m

Current Assets

36.9 m182.3 m164 m143.1 m87.5 m145.5 m110.8 m163.3 m

PP&E

607 k617 k584 k590 k534 k724 k635 k568 k

Total Assets

37.6 m194.8 m164.8 m144 m88.4 m146.6 m111.8 m164.2 m

Accounts Payable

15.2 m11.2 m10.6 m11.6 m13.6 m19 m15.8 m28.4 m

Current Liabilities

18.6 m19.1 m16.8 m19.8 m19.3 m23.1 m23.5 m43.5 m

Additional Paid-in Capital

255.2 m269.5 m306 m326.9 m437.8 m530.4 m535.2 m751.5 m

Retained Earnings

(236.3 m)(294.3 m)(327.9 m)(353.9 m)(444.3 m)(482.9 m)(523.1 m)(647.6 m)

Total Equity

18.9 m(24.7 m)(21.9 m)(27.1 m)103.9 m

Financial Leverage

2 x-7.9 x-7.5 x-5.3 x1.6 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(62.1 m)(95.7 m)(117.5 m)(198.6 m)

Depreciation and Amortization

56 k120 k163 k233 k

Inventories

(2.2 m)(124 k)531 k(5.6 m)

Accounts Payable

7.1 m316 k1.9 m11.5 m

Cash From Operating Activities

(52.6 m)(89.1 m)(101 m)(129.8 m)

Purchases of PP&E

(615 k)(173 k)(50 k)(297 k)

Cash From Investing Activities

(30.9 m)282 k(250 k)49.8 m

Cash From Financing Activities

89.2 m217.1 m16.4 m100.7 m

Income Taxes Paid

81 k55 k258 k45 k
USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(23 m)(27.4 m)(33.7 m)(26 m)(59.9 m)(38.6 m)(40.2 m)(64.6 m)

Accounts Receivable

6.3 m

Inventories

9.6 m

Accounts Payable

15.2 m11.2 m10.6 m11.6 m13.6 m19 m15.8 m28.4 m
USDY, 2017

Revenue/Employee

844.8

Financial Leverage

1.6 x

Synergy Pharmaceuticals Operating Metrics

Synergy Pharmaceuticals's Patent Applications was reported to be 3 in FY, 2016
FY, 2016

Patents (US)

21

Patent Applications

3

Patents (foreign)

8

Patents Pending

93

Synergy Pharmaceuticals Market Value History

Traffic Overview of Synergy Pharmaceuticals

Synergy Pharmaceuticals Online and Social Media Presence

Synergy Pharmaceuticals News and Updates

There's now an animated poop-emoji keyboard and we hope you're not eating right now

Have you ever wanted to message your friends about the consistency of your bowel movements, but strained to find the right words? Well it's time to sit back and relax, as a new animated poop-emoji keyboard is here to do all the talking for you.  SEE ALSO: Facebook's new emoji are finally availab…

Wall Street Takes a Breather After Steep Trump Rally

Wall Street was flat on Friday as investors refrained from making big bets ahead of the holiday season, but the three major indexes were still on track to post weekly gains.

Synergy Pharmaceuticals Company Life and Culture

You may also be interested in